BioAge Labs, Inc.
NASDAQBioAge Labs heads into its Q1 earnings today with options traders firmly positioned on the bullish side — an unusually clean read for a small-cap biotech. The clearest signal is the put/call ratio. At 0.36, it is running well below the 20-day average of 1.02, roughly one standard deviation beneath the norm. That marks a sharp reversal from April, when the PCR was running above 3.0…
Snapshot as of 14 May 2026
BioAge Labs heads into its Q1 earnings today with options traders firmly positioned on the bullish side — an unusually clean read for a small-cap biotech. The clearest signal is the put/call ratio. At 0.36, it is…
BioAge Labs enters its May 14 Q2 earnings call with a fresh analyst initiation, a strong Q1 beat in the bank, and options traders signalling more confidence than they've shown in months. The timing of Wednesday's BTIG…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BIOA — free to start on ORTEX.
Sign up for free →Open BIOA on ORTEX